Get the Stockscreener App
4.59
12.50%
0.51
After Hours:
4.59
Camp 4 Therapeutics Corp stock is traded at $4.59, with a volume of 90,925.
It is up +12.50% in the last 24 hours and up +27.86% over the past month.
Camp4 Therapeutics Corp is a clinical stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
See More
Previous Close:
$4.08
Open:
$3.99
24h Volume:
90,925
Relative Volume:
0.62
Market Cap:
$238.13M
Revenue:
$264.74M
Net Income/Loss:
$-49.71M
P/E Ratio:
-1.1206
EPS:
-4.0959
Net Cash Flow:
$-43.55M
1W Performance:
+2.23%
1M Performance:
+27.86%
6M Performance:
+201.97%
1Y Performance:
-4.97%
1-Day Range:
$3.99
$4.70
1-Week Range:
$3.89
$4.72
52-Week Range:
$1.305
$7.305
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Name
Camp 4 Therapeutics Corp
Sector
Industry
Phone
617-651-8867
Address
ONE KENDALL SQUARE, CAMBRIDGE, CA
Compare CAMP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
4.59 | 211.68M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-16-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-27-25 | Initiated | Wedbush | Outperform |
| Nov-05-24 | Initiated | JP Morgan | Overweight |
| Nov-05-24 | Initiated | Piper Sandler | Overweight |
| Nov-05-24 | Initiated | William Blair | Outperform |
| Aug-16-22 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-22-21 | Downgrade | Craig Hallum | Buy → Hold |
| Sep-24-21 | Reiterated | Craig Hallum | Buy |
| Jun-25-21 | Reiterated | Craig Hallum | Buy |
| Dec-18-20 | Downgrade | JP Morgan | Neutral → Underweight |
| Apr-17-20 | Upgrade | Jefferies | Hold → Buy |
| Mar-05-20 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Reiterated | Craig Hallum | Buy |
| Dec-20-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Jun-28-19 | Upgrade | Northland Capital | Market Perform → Outperform |
| May-29-19 | Downgrade | Goldman | Neutral → Sell |
| May-01-19 | Reiterated | Craig Hallum | Buy |
| Mar-25-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-25-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-21-18 | Upgrade | Craig Hallum | Hold → Buy |
| Dec-14-18 | Reiterated | B. Riley FBR | Buy |
| Dec-11-18 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Dec-11-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| Nov-27-18 | Initiated | Goldman | Neutral |
| Oct-15-18 | Initiated | Jefferies | Hold |
| Sep-28-18 | Reiterated | Craig Hallum | Hold |
| Apr-27-18 | Reiterated | Craig Hallum | Hold |
| Mar-08-18 | Downgrade | Craig Hallum | Buy → Hold |
| Feb-16-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
View All
Camp 4 Therapeutics Corp Stock (CAMP) Latest News
Guidance Update: What is Camp4 Therapeutics Corporations book value per shareEarnings Risk Summary & Reliable Price Breakout Alerts - baoquankhu1.vn
Regulatory RNA strategy presented for gene expression, Camp4 Therapeutics Corp outlines - Traders Union
Camp4 Therapeutics Corp unveils ASO approach to boost gene expression in SYNGAP1 treatment - Traders Union
Camp4 Therapeutics Corp commits to new therapies for rare and neurological diseases - Traders Union
CAMP Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
RBOT Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Analysts Have Conflicting Sentiments on These Healthcare Companies: Collegium Pharmaceutical (COLL) and Intellia Therapeutics (NTLA) - The Globe and Mail
Camp4 Therapeutics Corp engages with SYNGAP1 community in Poland family day event - Traders Union
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
Cantor Fitzgerald Remains a Buy on CAMP4 Therapeutics Corporation (CAMP) - The Globe and Mail
Market Moves: Can AUUDW maintain its current growth rateEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
CNTY PE Ratio & Valuation, Is CNTY Overvalued - Intellectia AI
How Camp4 Therapeutics Corporation stock reacts to job market dataMarket Sentiment Report & Weekly Chart Analysis and Guides - mfd.ru
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fed Meeting: Will Camp4 Therapeutics Corporation face regulatory challenges2025 Investor Takeaways & Low Volatility Stock Suggestions - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Moderna (MRNA) and NewAmsterdam Pharma Company (NAMS) - The Globe and Mail
Risk Check: Is TACT undervalued by DCF analysisQuarterly Portfolio Review & Safe Swing Trade Setup Alerts - baoquankhu1.vn
Is Camp4 Therapeutics Corporation stock a buy in volatile marketsJuly 2025 Update & Stepwise Trade Signal Implementation - mfd.ru
Is Camp4 Therapeutics Corporation being accumulated by smart money2025 Market WrapUp & AI Driven Stock Movement Reports - mfd.ru
Can Camp4 Therapeutics Corporation ride the EV waveMarket Trend Review & Free Verified High Yield Trade Plans - mfd.ru
BRID PE Ratio & Valuation, Is BRID Overvalued - Intellectia AI
WRAP PE Ratio & Valuation, Is WRAP Overvalued - Intellectia AI
Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
SY PE Ratio & Valuation, Is SY Overvalued - Intellectia AI
FMR LLC Increases Stake in Camp4 Therapeutics Corp: A Strategic Move in Biotechnology - GuruFocus
10 Best Online Therapy Platforms In 2026: Tested & Reviewed - Forbes
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Aprea Therapeutics (APRE) - The Globe and Mail
Camp4 Therapeutics shares slide after $30 million equity offering priced - MSN
Downgrade Watch: Can Camp4 Therapeutics Corporation ride the EV waveTrade Analysis Summary & Verified Swing Trading Watchlists - baoquankhu1.vn
Will Camp4 Therapeutics Corporation benefit from rising consumer demand2025 Sector Review & Verified Momentum Stock Alerts - mfd.ru
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA) and Cardiff Oncology (CRDF) - The Globe and Mail
Analysis Recap: Will Camp4 Therapeutics Corporation outperform the market in YEAR2025 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Retail Trends: Is CVD Equipment Corporation stock undervalued right nowExit Point & Low Volatility Stock Recommendations - baoquankhu1.vn
Market Outlook: Will Camp4 Therapeutics Corporation stock benefit from M AJuly 2025 Final Week & Growth Focused Stock Pick Reports - baoquankhu1.vn
Harbor Wellness Co. Partners with Fit Body Boot Camp for 4-Week Series on Injury Prevention and Proper Form - Sarasota Herald-Tribune
CAMP4 Therapeutics announces $28 million common stock offering - MSN
Signal Recap: Will Camp4 Therapeutics Corporation outperform the market in YEARMarket Growth Review & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
New CAMP4 hire receives option to buy 8,000 shares at $5.78 each in grant - Stock Titan
CAMP4 Therapeutics Corporation (CAMP) Upgraded to Buy: Here's Why - sharewise.com
CAMP: CMP-002 targets SYNGAP1 disorders with first-in-class therapy, entering clinic this year - TradingView
Published on: 2026-01-10 23:34:38 - ulpravda.ru
CAMP4 Therapeutics updates corporate investor presentation materials - TipRanks
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Scrip Asks... What Does 2026 Hold For Biopharma? Part 1: Capital Allocation And Dealmaking - Citeline News & Insights
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA) and Xencor (XNCR) - The Globe and Mail
Stock Recap: What hedge fund activity signals for Camp4 Therapeutics Corporation stockMarket Performance Report & Verified Technical Signals - Улправда
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sandoz Group Ltd (OtherSDZXF) and Denali Therapeutics (DNLI) - The Globe and Mail
CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Wedbush Initiates Coverage of Camp4 Therapeutics (CAMP) with Outperform Recommendation - MSN
Insilico’s big gain after Hong Kong listing: Finance Report - biocentury.com
Camp 4 Therapeutics Corp Stock (CAMP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Camp 4 Therapeutics Corp Stock (CAMP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Polaris Management Co. VII, L. | 10% Owner |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Nashat Amir | Director |
Sep 11 '25 |
Buy |
1.53 |
1,307,189 |
1,999,999 |
2,825,500 |
| Maricich Yuri | Chief Medical Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
6,060 |
| Gold Kelly | Chief Financial Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
67,877 |
| Mandel-Brehm Josh | Chief Executive Officer |
Sep 11 '25 |
Buy |
1.65 |
6,060 |
9,999 |
278,417 |
| Young Richard A | Director |
Sep 11 '25 |
Buy |
1.65 |
15,151 |
24,999 |
170,010 |
3.69%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):